Anti-Vascular Endothelial Growth Factor Therapeutics Market Forecast and Insights: Exploring Growth Trends, Market Size, and Emerging Opportunities
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The growth of the anti-vascular endothelial growth factor therapeutics market is predicted to be driven by a rise in the occurrence of ophthalmic conditions. The term ‘prevalence of ophthalmic diseases’ is used to indicate the number or percentage of people in a specific population who have been diagnosed with or show signs of certain eye diseases. Anti-vascular endothelial growth factor (VEGF) therapeutics work to decrease the occurrence of ophthalmic diseases by effectively managing conditions like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. The World Health Organization, a Switzerland-based global public health organization, reported in October 2022 that approximately 2.2 billion individuals globally are hampered with near or distance vision impairment, with 1 billion experiencing near or distance vision impairment. Of these, 88.4 million are grappling with refractive error, 94 million are affected by cataracts, 8 million live with age-related macular degeneration, and approximately 3.9 million are dealing with diabetic retinopathy. Thus, the rise in the occurrence of ophthalmic conditions is triggering the expansion of the anti-vascular endothelial growth factor therapeutics market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp
#What is the Anticipated CAGR of the Anti-Vascular Endothelial Growth Factor Therapeutics Market, and What Factors Will Drive It?
During recent years, there has been a slight increase in the size of the anti-vascular endothelial growth factor therapeutics market. Its size will expand from $12.2 billion in 2024 to $12.31 billion in 2025, representing a compound annual growth rate (CAGR) of 1.0%. This growth throughout the historic period may be credited to numerous factors including a surge in age-related macular degeneration, greater occurrence of diabetic retinopathy, advancements in diagnosing retinal disease, clinical effectiveness and efficiency, and a shift towards outpatient care.
The market for anti-vascular endothelial growth factor therapeutics is predicted to exhibit a steady rise in the upcoming years, projected to reach $13.49 billion in 2029 with a compound annual growth rate (CAGR) of 2.3%. This escalation during the forecast period can be credited to factors such as the aging populace and eye-related ailments, extended use in rectifying retinal disorders, advancement of cutting-edge therapeutics, heightened focus on early diagnosis and treatment, worldwide health initiatives, and availability of treatment options. Key market trends anticipated within this period encompass increased application in cancer therapy, emphasis on combined treatments in ophthalmology, investigation of biosimilar alternatives, studies on resistance methods, and synergy with imaging technologies.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10683
What Are the Key Market Innovations in theAnti-Vascular Endothelial Growth Factor Therapeutics Market Over the Coming Years?
Progress in therapeutic methods is a promising trend on the rise in the anti-vascular endothelial growth factor therapeutics market. Businesses in this field are embracing state-of-the-art therapeutic approaches to maintain a competitive edge. For instance, in May 2022, Ashvattha Therapeutics Inc., a clinical-stage biopharmaceutical firm from the US, published phase 1 safety data for healthy participants concerning subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) potential treatments, named D-4517.2. This groundbreaking therapy aims to address unfulfilled needs related to DME conditions and is under development for self-application using an autoinjector. The autoinjector D-4517.2 equips patients with the means to independently dispense the treatment monthly in the convenience of their own homes.
Who Are the Top Companies Driving Innovation and Growth in theAnti-Vascular Endothelial Growth Factor Therapeutics Market?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.
Order Your Report Now For A Swift Delivery:
Which Key Market Segments Comprise the Anti-Vascular Endothelial Growth Factor Therapeutics Market and Drive Its Revenue Growth?
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Subsegments:
1) By Eylea: Indications, Dosage Forms
2) By Lucentis: Indications, Dosage Forms
3) By Beovu: Indications, Dosage Forms
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10683&type=smp
Which Regions Are Emerging as Leaders in the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Reports Similar to the Gobal Anti-Vascular Endothelial Growth Factor Therapeutics Maret 2025, By The Business Research Company:
Insecticides Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insecticides-global-market-report
Crop Protection Chemicals Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/crop-protection-chemicals-global-market-report
Vector Control Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/vector-control-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
